Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharmaceutical patent strategy is often discussed like a binary choice: fight, settle, or fade away. But in practice, the real question is more uncomfortable—and more profitable:
Do you cut, keep, or cash in?
In a market where litigation costs can riva…

The clock is ticking—and commercial market access vendors are betting on the wrong time.
In pharma, timing isn’t just strategy. It’s survival.
As drug patent clocks run down, the industry enters a high-stakes transition: originators face erosion, payer…

Pharma procurement teams are sitting on a powerful due diligence lever—and most are ignoring it.
Paragraph IV filings—those high-stakes challenges to brand-name drug patents—aren’t just legal events. They’re market signals. They’re timing signals. And,…

Drug patent expiry dates aren’t just legal milestones—they’re commercial inflection points. And yet, too many pharma teams treat them like a back-office calendar item instead of a front-line growth strategy.
Here’s the agitation: when a patent cliff ap…

Sell the line before the patent breaks. That’s the uncomfortable truth many pharma suppliers learn too late.
In solid dose manufacturing, the “race” isn’t won when the patent expires. It’s won when the customer decides—months or even years earlier—what…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/